12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dulaglutide: Phase III data

Top-line data from the double-blind, international Phase III AWARD-1 trial in 978 Type II diabetics on metformin and pioglitazone showed that once-weekly 1.5 mg subcutaneous dulaglutide met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo. Additionally, the trial was designed to assess superiority of both once-weekly 0.75 and 1.5 mg doses of dulaglutide to twice-daily 5 µg Byetta exenatide if...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >